What's happened
Lilly has reported growth in the oral GLP-1 pill market and expansion plans, with one-third of new oral-GLP-1 patients on Foundayo. The company is also building a new manufacturing facility in Houston and reiterating its commitment to meeting rising demand as Medicare coverage broadens access to obesity drugs.
What's behind the headline?
Analysis
- Lilly is expanding its GLP-1 footprint as Medicare coverage broadens access, signaling a shift in the obesity-drug market.
- The Foundayo pill is gaining traction, with one-third of new oral-GLP-1 patients using it, while Zepbound remains a major driver for patients with higher weight and complications.
- Lilly’s new Houston manufacturing site underscores a broader strategic push to secure supply, potentially pressuring rivals and shaping pricing dynamics.
- Employers are reevaluating GLP-1 coverage amid rising costs, a factor that could affect access beyond Medicare, with some companies cutting or limiting benefits.
- The regulatory and manufacturing expansion implies a race to scale output and capture a larger share of patients entering GLP-1 therapies.
How we got here
The articles show Lilly’s push to grow its GLP-1 portfolio, including the Foundayo pill and Zepbound injections, against expanding Medicare coverage and corporate manufacturing investments in the U.S. The shift in coverage and manufacturing capacity is reshaping competition with Novo and affecting employer drug coverage decisions.
Our analysis
CNBC: Lilly executives say Foundayo accounts for about one-third of new oral-GLP-1 patients and discuss Medicare Bridge program access; Reuters: Lilly breaks ground on Houston manufacturing facility tied to Foundayo production and broader supply ambitions; Independent: employers reassessing GLP-1 coverage amid rising costs, with PepsiCo, Cigna, and Starbucks cited. Quotes and data reflect ongoing coverage and market dynamics.
Go deeper
- How is Medicare coverage expanding access to GLP-1 drugs influencing patient choices?
- What impact will Lilly’s Houston plant have on prices and supply in the near term?
- Will employers continue to modify GLP-1 coverage as costs rise?
More on these topics
-
United States - Country in North America
The United States of America, commonly known as the United States or America, is a country mostly located in central North America, between Canada and Mexico.
-
Eli Lilly and Company - Pharmaceutical company
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Col. Eli Lilly, a
-
Novo Nordisk - Danish pharmaceutical company
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company...
-
Medicare - Wikimedia disambiguation page
Medicare is a government national health insurance program in the United States, begun in 1965 under the Social Security Administration and now administered by the Centers for Medicare and Medicaid Services.